Radiosensitizing the SUMO stress response intensifies single-dose radiotherapy tumor cure

Cheng Jin, Liyang Zhao, Sahra Bodo, Prashanth K.b. Nagesh, Rajvir Singh, Adam O. Michel, Regina Feldman, Zhigang Zhang, Simon N. Powell, Zvi Fuks, Richard KolesnickJCI 2025 · DOI

TL;DR

This paper demonstrates that combining a VEGFR2 inhibitor (DC101) with single-dose radiotherapy (SDRT) significantly enhances tumor cure by sensitizing the SUMO stress response (SSR) and impairing DNA repair. Crucially, this radiosensitization is tumor-specific, showing no increased toxicity to normal tissues, which could expand the applicability of SDRT to previously untreatable lesions.

What Problem Does This Paper Address?

Single-dose radiotherapy (SDRT) is a highly effective and curative cancer treatment, but its use is limited. Approximately half of oligometastatic lesions cannot be treated with SDRT because they are located near radiosensitive normal organs at risk (OARs). To avoid damaging these OARs, the radiation dose to the tumor must be reduced, which compromises its effectiveness and leads to a high risk of local recurrence. The challenge, therefore, is to find a way to increase the tumor's sensitivity to radiation without increasing the toxicity to surrounding healthy tissues, thereby enabling SDRT to treat a wider range of tumors.

Methods

The researchers investigated the radiosensitizing potential of DC101, a VEGFR2 antagonist, in combination with SDRT. They used murine fibrosarcoma (MCA/129) and Lewis lung carcinoma (LLC) models.

Key techniques included:

  • In vivo tumor models: Tumors were grown in mice, and their response to SDRT with or without DC101 pretreatment was assessed.
  • Western blotting: Used to detect and quantify SUMO2/3 conjugates, a marker of the SUMO stress response (SSR).
  • Immunofluorescence microscopy: Employed to visualize and quantify DNA damage repair foci, specifically γH2AX, MDC1, and BRCA1, which are indicators of DNA double-strand breaks (DSBs) and their repair. DNA-PKcs foci were also examined to assess the non-homologous end joining (NHEJ) repair pathway.
  • Histological analysis: Used to assess endothelial cell apoptosis in the small intestine.
  • Animal survival studies: To evaluate the lethality of gastrointestinal-acute radiation syndrome (GI-ARS).
  • Dose-response modeling: Using GraphPad Prism and R to analyze tumor control doses (TCDs) and calculate odds ratios.

The novel aspect here is the timed administration of the antiangiogenic drug (DC101) precisely one hour before SDRT, which is hypothesized to optimally derepress ASMase activity and enhance the SSR.

Datasets

Not discussed in the paper. The study relies on experimental data generated from mouse models.

Key Insights and Ideas

  • SDRT's unique mechanism: Unlike conventional fractionated radiotherapy, SDRT's tumor cure relies on a dual mechanism: damaging tumor microvasculature (leading to hypoxia and SSR) and directly damaging tumor DNA.
  • The SUMO stress response (SSR) as a target: SDRT induces an SSR in tumor cells, which inactivates DNA repair enzymes, making tumors more susceptible to radiation damage.
  • VEGF's role in regulating ASMase: Vascular endothelial growth factor (VEGF) normally inhibits acid sphingomyelinase (ASMase) in tumor vasculature. Blocking VEGF with DC101 derepresses ASMase.
  • Timing is critical: Optimal radiosensitization occurs when DC101 is administered approximately 1 hour before SDRT, allowing sufficient time for ASMase activation and subsequent SSR induction.
  • Tumor-specific radiosensitization: DC101 enhances SDRT's effect on tumors but does not sensitize normal tissues like the small intestine to radiation damage or lethality. This is attributed to normal tissues not being under the same VEGF regulation as tumor vasculature.

Key Results

  • Significant radiosensitization: DC101 pretreatment resulted in a 4-6 Gy left shift in the SDRT dose-response curve for tumor cure in both fibrosarcoma and Lewis lung carcinoma models.
  • Enhanced SSR: DC101 significantly increased SUMOylation (a marker of SSR) in tumor cells after SDRT, even at lower radiation doses.
  • Impaired DNA repair: DC101 treatment, in conjunction with SDRT, significantly attenuated the resolution of DNA damage markers (γH2AX, MDC1, BRCA1 foci), indicating impaired DNA double-strand break repair. This effect was observed even at doses that would normally allow for repair.
  • No impact on NHEJ: DC101 did not affect the accrual or resolution of DNA-PKcs foci, suggesting that the radiosensitization primarily targets homologous recombination repair (HRR) and not the NHEJ pathway.
  • No normal tissue toxicity: DC101 did not increase endothelial cell apoptosis in the small intestine or enhance lethality from gastrointestinal-acute radiation syndrome at clinically relevant SDRT doses.

Limitations and Future Work

  • Preclinical models: While promising, the findings are based on murine tumor models. Further validation in human clinical trials is necessary.
  • Oligometastatic lesions: The study focused on specific tumor types. Its applicability to the broad spectrum of oligometastatic lesions needs to be confirmed.
  • Translational challenges: Translating the precise timing of DC101 administration and its integration into clinical SDRT protocols will require careful planning.

The authors suggest that this approach, termed "perfusion-modulated dose sculpting" (PMDS) combined with timed antiangiogenic therapy, could potentially treat lesions that are currently intractable due to their proximity to OARs. They intend to test this strategy clinically in the near future. The potential to expand SDRT's reach and offer a less toxic alternative to surgery or chemotherapy for many cancer patients is a significant future direction.

Summary updated

Abstract

Single-dose radiotherapy (SDRT) is a highly curative modality that may transform radiotherapy practice. Unfortunately, only ~50% of oligometastatic lesions are SDRT treatable due to adjacent radiosensitive normal organs at risk. Here, we address the extent to which an antiangiogenic drug, VEGFR2-antagonist DC101, radiosensitizes SDRT using murine MCA/129 fibrosarcomas and Lewis lung carcinomas, which display a dose range for SDRT lesional eradication virtually identical to that employed clinically (10-30 Gy). SDRT induces unique tumor cure, stimulating rapid endothelial acid sphingomyelinase (ASMase)/ceramide signaling that yields marked vasoconstriction and perfusion defects in tumor xenografts and human oligometastases. Ensuing tumor parenchymal oxidative damage initiates a SUMO stress response (SSR), which inactivates multiple homologous recombination repair enzymes, radiosensitizing all tumor types. While VEGF inhibits neo-angiogenic ASMase, optimal radiosensitization occurs only upon antiangiogenic drug delivery at ~1 hour preceding SDRT. Obeying these principles, we find DC101 radiosensitizes SSR, DNA double-strand break unrepair, and tumor cure by 4-8 Gy at all clinically relevant doses. Critically, DC101 fails to sensitize small intestinal endothelial injury or lethality from the gastrointestinal-acute radiation syndrome. Whereas normal tissues appear not to be under VEGF regulation nor sensitized by our approach, its application might render many currently intractable oligometastatic lesions susceptible to SDRT eradication.
BibTeX
@inproceedings{jin2025radiosensitizing,
  author = {Cheng Jin and Liyang Zhao and Sahra Bodo and Prashanth K.B. Nagesh and Rajvir Singh and Adam O. Michel and Regina Feldman and Zhigang Zhang and Simon N. Powell and Zvi Fuks and Richard Kolesnick},
  title = {{Radiosensitizing the SUMO stress response intensifies single-dose radiotherapy tumor cure}},
  booktitle = {JCI},
  year = {2025},
  doi = {10.1172/jci.insight.153601},
}
Figure